{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:20:52Z","timestamp":1789791652516,"version":"4.0.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nirmatrelvir\/ritonavir was recently granted emergency use authorization for mild to moderate coronavirus disease 2019. Drug\u2013drug interactions between ritonavir and tacrolimus are underappreciated by nontransplant providers. We describe 2 solid organ transplant recipients prescribed nirmatrelvir\/ritonavir for outpatient use who developed tacrolimus toxicity requiring hospitalization and were managed with rifampin for toxicity reversal.<\/jats:p>","DOI":"10.1093\/ofid\/ofac238","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T11:48:30Z","timestamp":1652442510000},"source":"Crossref","is-referenced-by-count":30,"title":["Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir\/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-336X","authenticated-orcid":false,"given":"Dusten T","family":"Rose","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ascension Seton, Dell Seton Medical at The University of Texas , Austin, Texas , USA"},{"name":"College of Pharmacy, University of Texas at Austin , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurin M","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dell Medical School, University of Texas at Austin , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A","family":"Bedard","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ascension Seton, Dell Seton Medical at The University of Texas , Austin, Texas , USA"},{"name":"Kidney and Pancreas Transplant Program, Dell Seton Medical Center, University of Texas at Austin , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin E","family":"Mondy","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Dell Medical School, University of Texas at Austin , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Dell Medical School, University of Texas at Austin , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C","family":"Gamble","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ascension Seton, Dell Seton Medical at The University of Texas , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda T","family":"Gee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ascension Seton, Dell Seton Medical at The University of Texas , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A","family":"Kundra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dell Medical School, University of Texas at Austin , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ascension Seton, Dell Seton Medical at The University of Texas , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K","family":"Lee","sequence":"additional","affiliation":[{"name":"Kidney and Pancreas Transplant Program, Dell Seton Medical Center, University of Texas at Austin , Austin, Texas , USA"},{"name":"Division of Nephrology, Department of Internal Medicine, Dell Seton Medical Center, University of Texas at Austin , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"2022073010004023100_ofac238-B1","article-title":"COVID data tracker","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"2022073010004023100_ofac238-B2","volume-title":"Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid","author":"Pfizer, Inc","year":"2021"},{"key":"2022073010004023100_ofac238-B3","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ajt.13111","article-title":"Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir","volume":"15","author":"Badri","year":"2015","journal-title":"Am J Transplant"},{"key":"2022073010004023100_ofac238-B4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/apc.2012.0169","article-title":"Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review","volume":"26","author":"van Maarseveen","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"2022073010004023100_ofac238-B5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2022073010004023100_ofac238-B6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"2022073010004023100_ofac238-B7","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/ajt.16364","article-title":"COVID-19 in lung transplant recipients: a multicenter study","volume":"21","author":"Saez-Gim\u00e9nez","year":"2021","journal-title":"Am J Transplant"},{"key":"2022073010004023100_ofac238-B8","doi-asserted-by":"crossref","first-page":"e13388","DOI":"10.1111\/tid.13388","article-title":"A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient","volume":"23","author":"Thammathiwat","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2022073010004023100_ofac238-B9","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","article-title":"Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect","volume":"75","author":"Stader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022073010004023100_ofac238-B10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/00912709922007499","article-title":"Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers","volume":"39","author":"Hebert","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"2022073010004023100_ofac238-B11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1345\/aph.19069","article-title":"Renal allograft dysfunction associated with rifampin-tacrolimus interaction","volume":"34","author":"Chenhsu","year":"2000","journal-title":"Ann Pharmacother"},{"key":"2022073010004023100_ofac238-B12","first-page":"388","article-title":"Decreased tacrolimus levels after administration of rifampin to a patient with renal transplant","volume":"66","author":"Naylor","year":"2013","journal-title":"Can J Hosp Pharm"},{"key":"2022073010004023100_ofac238-B13","article-title":"Norvir prescribing information","author":"AbbVie Inc","year":"2016"},{"key":"2022073010004023100_ofac238-B14","article-title":"Fact sheet for healthcare providers: emergency use authorization for Paxlovid","author":"US Food and Drug Administration","year":"2022"},{"key":"2022073010004023100_ofac238-B15","article-title":"COVID drug interactions","author":"Liverpool Drug Interactions Group","year":"2022"},{"key":"2022073010004023100_ofac238-B16","article-title":"American Society of Transplantation statement on oral antiviral therapy for COVID-19 for organ transplant recipients","author":"Kumar","year":"2022"},{"key":"2022073010004023100_ofac238-B17","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16955","article-title":"Nirmatrelvir\/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants [manuscript published online ahead of print 11 January 2022]","author":"Lange","year":"2022","journal-title":"Am J Transplant"},{"key":"2022073010004023100_ofac238-B18","article-title":"COVID-19 treatment guidelines. Antiviral therapy: ritonavir-boosted nirmatrelvir (Paxlovid)","author":"National Institutes of Health"},{"key":"2022073010004023100_ofac238-B19","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.17027","article-title":"Early clinical experience with nirmatrelvir\/ritonavir for the treatment of COVID-19 in solid organ transplant recipients [manuscript published online ahead of print 12 March 2022]","author":"Salerno","year":"2022","journal-title":"Am J Transplant"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac238\/43698839\/ofac238.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac238\/45028942\/ofac238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac238\/45028942\/ofac238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T10:02:38Z","timestamp":1659175358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac238\/6585265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac238","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,5,13]]},"article-number":"ofac238"}}